Company news

United Therapeutics Corporation (NASDAQ:UTHR) news

Every United Therapeutics Corporation press release and news update in one place — announcements, filings coverage, and company updates for investors.

United Therapeutics Corporation (NASDAQ:UTHR) news

Press releases & updates

United Therapeutics Corporation Announces Accelerated Share Repurchase Agreement for Remainder of $2.0 Billion Authorization

United Therapeutics Corporation Announces FDA Acceptance of Supplemental New Drug Application for Nebulized Tyvaso® to Treat Idiopathic Pulmonary Fibrosis

United Therapeutics Corporation Announces Participation at Upcoming Investor Conferences

United Therapeutics Presents Data at The European Society of Cardiology Congress 2026 and The European Respiratory Society International Congress 2026

United Therapeutics Corporation Announces FDA Filing Acceptance of New Drug Application for Ralinepag to Treat Pulmonary Arterial Hypertension

United Therapeutics Corporation Announces Full Enrollment of the TETON-PPF Study of Inhaled Treprostinil for the Treatment of Progressive Pulmonary Fibrosis

United Therapeutics Corporation Reports Second Quarter 2026 Financial Results

FDA approves Pluvicto for PSMA+ metastatic hormone-sensitive prostate cancer (mHSPC), advancing potential new standard of care across metastatic disease

United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Published in The Lancet

United Therapeutics Corporation Announces Appointment of Victor Dzau to its Board of Directors

United Therapeutics Corporation to Report Second Quarter 2026 Financial Results Before Market Open on Wednesday, August 5, 2026

United Therapeutics Corporation Acquires Thymmune Therapeutics

United Therapeutics Corporation Announces FDA Approval of the LungFX™ Device for Centralized Ex Vivo Lung Perfusion

United Therapeutics Corporation to Present at the Jefferies Global Healthcare Conference

United Therapeutics Corporation Announces TETON-1 Study of Tyvaso Published in The New England Journal of Medicine and Presented at ATS 2026

United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Presented at ATS 2026

United Therapeutics Corporation Announces FDA Clearance to Proceed with UHeart Xenotransplantation Clinical Trial

Varda Space Industries and United Therapeutics Collaborate to Advance Microgravity-Enabled Treatments for Rare Pulmonary Disease

United Therapeutics Corporation to Present at the RBC Capital Markets Global Healthcare Conference

United Therapeutics Corporation Presents New Data from TETON-1, ADVANCE OUTCOMES, and Additional Research in Pulmonary Hypertension and Pulmonary Fibrosis at ATS 2026

Unituxin (United Therapeutics) Market Research Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts, 2020-2025, 2025-2030F, 2035F

United Therapeutics Corporation Reports First Quarter 2026 Financial Results

United Therapeutics Corporation Announces Retirement of Professor Raymond Dwek, C.B.E., F.R.S., From Its Board of Directors

United Therapeutics Corporation to Report First Quarter 2026 Financial Results Before Market Open on Wednesday, May 6, 2026

United Therapeutics Corporation Presents New Data Spanning Pulmonary Hypertension Treatment, Lung Donor Expansion, and Xenotransplantation at ISHLT 2026

United Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for miroliverELAP® for Treatment of Acute Liver Failure

United Therapeutics Corporation Announces TETON-1 Pivotal Study of Tyvaso® Meets Primary Endpoint for Treatment of Idiopathic Pulmonary Fibrosis, Exceeding Impressive Treatment Effect Seen in TETON-2

United Therapeutics Corporation Announces Full Results of TETON-2 Phase 3 Clinical Trial Published in The New England Journal of Medicine

United Therapeutics Corporation Announces $2 Billion Stock Repurchase Authorization and Enters into $1.5 Billion Accelerated Share Repurchase Program

United Therapeutics Corporation to Present at the Leerink Global Healthcare Conference

United Therapeutics Corporation Announces Ralinepag Achieved 55% Reduction in Risk of Clinical Worsening in Pivotal Pulmonary Arterial Hypertension Study, Delivering Exceptional, Highly Statistically Significant Efficacy

United Therapeutics Corporation Reports Fourth Quarter and Full Year 2025 Financial Results

United Therapeutics Corporation to Present at the TD Cowen 46th Annual Health Care Conference

United Therapeutics Corporation to Report Fourth Quarter and Full Year 2025 Financial Results Before the Market Opens on Wednesday, February 25, 2026

United Therapeutics Announces Positive Results from Phase 1 Study of miroliverELAP® in Patients with Acute Liver Failure

United Therapeutics Corporation Announces Appointment of Kevin J. Tracey to its Board of Directors

United Therapeutics Corporation to Present at the 44th Annual J.P. Morgan Healthcare Conference

United Therapeutics Corporation to Present at Upcoming Investor Conferences

United Therapeutics Corporation Announces First Transplant in EXPAND Clinical Trial of UKidney in Patients With End-Stage Renal Disease

United Therapeutics Corporation Reports Record Third Quarter 2025 Financial Results

United Therapeutics Corporation to Report Third Quarter 2025 Financial Results Before Market Open on Wednesday, October 29, 2025

United Therapeutics to Feature Clinical Data at the CHEST 2025 Annual Meeting

United Therapeutics Corporation to Review Data from the Successful TETON-2 Pivotal Study of Nebulized Tyvaso® in Idiopathic Pulmonary Fibrosis

United Therapeutics Corporation to Present at the Bernstein 2nd Annual Healthcare Forum

United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the European Respiratory Society Congress

United Therapeutics Corporation Announces TETON-2 Pivotal Study of Tyvaso® Meets Primary Endpoint for the Treatment of Idiopathic Pulmonary Fibrosis

United Therapeutics Corporation to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

MannKind Announces Expansion of United Therapeutics Collaboration for Second Inhaled Therapy

3D Systems Reports Second Quarter 2025 Financial Results

United Therapeutics Corporation Announces $1 Billion Accelerated Share Repurchase Program